Skip to content
DataLookout
Menu

NCT05645523

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 22 versions: 20 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 5 words
    • Enrollment increased: 25 → 35 participants
    • Site details revised at 3 of 3 sites
  2. Minor Site contacts updated at 1 of 3 sitesv21
  3. Notable Enrollment target: 15 to 25
    • Site contacts updated at 1 of 3 sites
    v19
  4. Minor Study sites: 1 to 3v18
  5. Minor Site contact updatedv17
Show 14 earlier versionsHide 14 earlier versions
  1. Notable Primary and study completion dates: Dec 2025 to Dec 2026
    • Eligibility criteria expanded, about 8 words
    • Primary endpoints revised (2)
    v16
  2. Minor Start date changed from estimate of Nov 2023 to Oct 24, 2023v14
  3. Minor Start date: Oct 2023 to Nov 2023v13
  4. Minor Start date: Sep 2023 to Oct 2023v12
  5. Minor Start date: Aug 2023 to Sep 2023v11
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v10
  7. Minor Start date: Jul 2023 to Aug 2023v9
  8. Minor Start date: Jun 2023 to Jul 2023v8
  9. Minor Start date: May 2023 to Jun 2023v7
  10. Minor Start date: Apr 2023 to May 2023v6
  11. Minor Start date: Mar 2023 to Apr 2023v5
  12. Minor Start date: Feb 2023 to Mar 2023v4
  13. Minor Start date: Jan 2023 to Feb 2023v3
  14. Minor Start date: Dec 2022 to Jan 2023v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful
Timeframe: During surgery (Intraoperatively)
Percentage of patients with grade 3 or higher adverse events related to ICG use
Timeframe: From the time of ICG administration to 24 hours after surgery (post-surgery)

Arms and interventions

Indocyanine green (ICG)Experimental

Participants will receive Indocyanine green intraoperatively.

Drugs: Indocyanine Green

Sites

3 sites in 1 country